Leerink Partners analyst, Jonathan Chang sees bluebird bio (NASDAQ: BLUE) gene therapy LentiGlobin as the key value driver for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE